| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the *Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland; Stanford University, Stanford, California; Wayne State University, Detroit, Michigan; University of Illinois, Chicago, Illinois; ¶Information Management Services, Inc, Rockville, Maryland; and ||Columbia University, New York, New York.
Address reprint requests to: Dr. Louise A. Brinton, 6120 Executive Blvd., Room 7068, Bethesda, MD 20852-7234; e-mail: brinton{at}nih.gov.
OBJECTIVE: To assess the long-term effects of ovulation-stimulating drugs on the risk of ovarian cancer.
METHODS: A retrospective cohort study of 12,193 eligible study subjects (median age 30 years) who were evaluated for infertility during the period of 1965–1988 at 5 clinical sites identified 45 subsequent ovarian cancers in follow-up through 1999. Standardized incidence ratios compared the risk of cancer among the infertile patients to the general population, whereas analyses within the cohort allowed the derivation of rate ratios for drug usage compared with no usage after adjustment for other ovarian cancer predictors.
RESULTS: The infertility patients had a significantly elevated ovarian cancer risk compared with the general population (standardized incidence ratio 1.98, 95% confidence intervals [CI] 1.4, 2.6). When patient characteristics were taken into account and risks assessed within the infertile women, the rate ratios associated with ever usage were 0.82 (95% CI 0.4, 1.5) for clomiphene and 1.09 (95% CI 0.4, 2.8) for gonadotropins. There were higher, albeit nonsignificant, risks with follow-up time, with the rate ratios after 15 or more years being 1.48 (95% CI 0.7, 3.2) for exposure to clomiphene (5 exposed cancer patients) and 2.46 (95% CI 0.7, 8.3) for gonadotropins (3 exposed cancer patients). Although drug effects did not vary by causes of infertility, there was a slightly higher risk associated with clomiphene use among women who remained nulligravid, based on 6 exposed patients (rate ratio 1.75; 95% CI 0.5, 5.7).
CONCLUSION: The results of this study generally were reassuring in not confirming a strong link between ovulation-stimulating drugs and ovarian cancer. Slight but nonsignificant elevations in risk associated with drug usage among certain subgroups of users, however, support the need for continued monitoring of long-term risks.
LEVEL OF EVIDENCE: II-2
This article has been cited by other articles:
|
|
 |
|
  A. Jensen, H. Sharif, J. H. Olsen, and S. K. Kjaer Risk of Breast Cancer and Gynecologic Cancers in a Large Population of Nearly 50,000 Infertile Danish Women Am. J. Epidemiol., July 1, 2008; 168(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.G. Hannibal, A. Jensen, H. Sharif, and S.K. Kjaer Risk of thyroid cancer after exposure to fertility drugs: results from a large Danish cohort study Hum. Reprod., February 1, 2008; 23(2): 451 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Popovsky Jewish Perspectives on the Use of Preimplantation Genetic Diagnosis J. Law Med. Ethics, December 1, 2007; 35(4): 699 - 711. [PDF]
|
|
|
|
 |
|
 F Baylis and C McLeod The stem cell debate continues: the buying and selling of eggs for research J. Med. Ethics, December 1, 2007; 33(12): 726 - 731. [Full Text] [PDF]
|
|
|
|
|
|
A. Melin, P. Sparen, and A. Bergqvist The risk of cancer and the role of parity among women with endometriosis Hum. Reprod., November 1, 2007; 22(11): 3021 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Burdette, R. M. Oliver, V. Ulyanov, S. M. Kilen, K. E. Mayo, and T. K. Woodruff Ovarian Epithelial Inclusion Cysts in Chronically Superovulated CD1 and Smad2 Dominant-Negative Mice Endocrinology, August 1, 2007; 148(8): 3595 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Choi, A. S. T. Wong, H.-F. Huang, and P. C. K. Leung Gonadotropins and Ovarian Cancer Endocr. Rev., June 1, 2007; 28(4): 440 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Terry, W. C. Willett, J. W. Rich-Edwards, and K. B. Michels A Prospective Study of Infertility Due to Ovulatory Disorders, Ovulation Induction, and Incidence of Breast Cancer Arch Intern Med, December 11, 2006; 166(22): 2484 - 2489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Basille, F. Olivennes, J. Le Calvez, N. Beron-Gaillard, G. Meduri, C. Lhomme, P. Duvillard, J. Benard, and P. Morice Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours Hum. Reprod., December 1, 2006; 21(12): 3241 - 3245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Althuis, K. S. Moghissi, C. L. Westhoff, B. Scoccia, E. J. Lamb, J. H. Lubin, and L. A. Brinton Uterine Cancer after Use of Clomiphene Citrate to Induce Ovulation Am. J. Epidemiol., April 1, 2005; 161(7): 607 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Gershenson Fertility-Sparing Surgery for Malignancies in Women J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 43 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Fertility Drugs and Ovarian Cancer: No Apparent Link Journal Watch Women's Health, August 4, 2004; 2004(804): 3 - 3. [Full Text]
|
|
|
|
 |
|
 Are Infertility and Ovarian Cancer Related? Journal Watch (General), July 6, 2004; 2004(706): 4 - 4. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
